None listed
Conditions
Brief summary
This study aims to evaluate the safety and tolerability of an experimental new drug. This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The total maximum study duration for participants is 36-39 days. Cohorts 1, 2, 3, 5 and 6: Single dose of GSBR-1290 or placebo administered on Day 1 under fasted conditions. Cohorts 4 (food effect): Single dose of GSBR-1290 or placebo administered on Day 1 under fasted conditions and another dose administered on Day 4 under fed conditions (total of 2 doses). In this study, up to 48 healthy volunteers will be enrolled across various cohorts receiving single ascending doses of the study drug. All participants will have to remain confined in the study center as required (between Days 1 to 7) depending on the cohort assigned and undergo blood tests and answer questions regarding their health
Interventions
GSBR-1290 is an orally available Glucagon-like peptide receptor agonist (GLP-1RA) being developed for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity. 24 Participants have been dosed to date. 48 Healthy volunteers total will be enrolled in a total of 6 cohorts (Cohorts 1 to 6) in this study. Each Cohort will enroll 8 participants with 6 participants randomized to receive GSBR-1290 and 2 participants randomized to receive placebo. All doses will be supervised and documented by site s
GSBR-1290 is an orally available Glucagon-like peptide receptor agonist (GLP-1RA) being developed for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity. 24 Participants have been dosed to date. 48 Healthy volunteers total will be enrolled in a total of 6 cohorts (Cohorts 1 to 6) in this study. Each Cohort will enroll 8 participants with 6 participants randomized to receive GSBR-1290 and 2 participants randomized to receive placebo. All doses will be supervised and documented by site staff. GSBR-1290 oral capsule will be provided at different ascending dose levels cohorts. Cohorts 1, 2, 3, 5 and 6 will receive doses in the range of 1mg to 540mg of GSBR-1290 and placebo on Day 1 orally. Cohort 4 will receive 90mg, or other dose to be determined by the Safety Review Committee in the range of 1mg to 540mg, GSBR-1290 or placebo administered on Day 1 under fasted conditions and another dose administered on Day 4 under fed conditions with total of 2 doses being administered orally. Dose levels for each cohort may change based on emerging safety and PK data upon review by the Safety Review Committee (SRC) meeting following each cohort. Cohorts will be does in a sequentially escalating order, unless the SRC determines otherwise in the interest of participant safety. If participants experience any clinically significant AEs during the confinement period, they may remain in the clinical facility for further observation at the discretion of the PI.
Sponsors
Gasherbrum Bio Pty Ltd. (Australian entity of ShouTi Inc)
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver)
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects 2. Adult males and females, 18 to 55 years of age (inclusive) at screening 3. Body mass index greater than or equal to 18.0 and less than or equal to 30.0 kg/m2, with a body weight (to 1 decimal place) greater than or equal to 45 kg at screening 4. Medically healthy without clinically significant abnormalities at the screening visit and prior to dosing at the timepoints indicated in the Schedules of Assessments (SoA) 5. Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 3 months prior to first study drug administration and have a negative breath test for cotinine at the screening visit and at check-in on Day -1. 6. Female volunteers must be of nonchildbearing potential i.e., surgically sterilized or postmenopausal or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use an acceptable method of contraception from signing the consent form until at least 30 days after the last dose of the study drug 7. Male volunteers must agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception from signing the consent form until at least 90 days after the last dose of study drug
Exclusion criteria
1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically significant. 2. Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications. 3. Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma). 4. Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia 5. Use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 3 months prior to the first study drug administration. 6. History of risk factors for torsade de pointes (including a family history of long QT syndrome or sudden cardiac death) or a known arrythmia. 7. Liver function test results elevated more than 1.5-fold above the upper limit of normal (ULN) for gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), aspartate aminotransferase (AST) or alanine aminotransferase (ALT). Volunteers with ALP and/or ALT/AST above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants 8. Liver function tests outside the normal range for bilirubin (total, conjugated and unconjugated). 9. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit. 10. Presence or having sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs. 11. Estimated creatinine clearance (CrCl) less than 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN. 12. History of substance abuse or alcohol abuse (defined as more than 10 standard drinks per week or regularly consuming more than 4 standard drinks on any one day; where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc./Vol], 100 mL wine [12% Alc./Vol], 30 mL spirit [40% Alc./Vol]) within 12 weeks prior to the screening visit. 13. Positive drugs of abuse or alcohol breath test results at the screening visit or at check-in (Day -1). 14. Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication.
Outcome results
None listed